4000-520-616
欢迎来到免疫在线！(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
产品库 品牌馆 现货促销 技术交流 新闻动态 联系我们
MedChemExp
主营：主营：抑制剂、激动剂、API
咨询热线电话
4000-520-616
公司首页 公司介绍 产品中心 新闻动态 联系方式 在线下单
当前位置： 首页 > 产品中心 > Small_molecule > Medchemexpress/（+）-JQ-1（同义词：JQ1）/HY-13030/1g
商品详细Medchemexpress/（+）-JQ-1（同义词：JQ1）/HY-13030/1g
Medchemexpress/（+）-JQ-1（同义词：JQ1）/HY-13030/1g
Medchemexpress/（+）-JQ-1（同义词：JQ1）/HY-13030/1g
商品编号： HY-13030-10mM*1mLinDMSO
品牌： MedChemExp
市场价： ¥1540.00
美元价： 924.00
产地： 美国(厂家直采)
公司：
产品分类： 小分子
公司分类： Small_molecule
联系Q Q： 3392242852
电话号码： 4000-520-616
电子邮箱： info@ebiomall.com
立即询价
商品介绍
(+)-JQ-1isaBETbromodomaininhibitor,withIC50of77nM/33nMforthefirstandsecondbromodomain(BRD4(1/2)).

CustomerValidation

  • •NatChemBiol.2016Jul;12(7):504-10.
  • •GenomeRes.2017Nov;27(11):1830-1842.
  • •Leukemia.2017Oct;31(10):2037-2047.
  • •GenesDev.2017Jul19.
  • •PLoSPathog.2016Oct20;12(10):e1005950.
  • •CancerLett.2017May31;402:100-109.
  • •JMedChem.2017Jun22.
  • •Metabolism.2016Oct;65(10):1478-88.
  • •MolCancerTher.2016Jun;15(6):1217-26.
  • •BiochimBiophysActa.2016Dec;1859(12):1527-1537.
  • •ACSChemBiol.2015Aug21;10(8):1770-7.
  • •JBiolChem.2016Nov4;291(45):23756-23768.
  • •JAgricFoodChem.2017Jun7;65(22):4384-4394.
  • •JCellBiochem.2017Jan6.
  • •HarvardMedicalSchoolLINCSLIBRARY
Description

(+)-JQ-1isaBETbromodomaininhibitor,withIC50of77nM/33nMforthefirstandsecondbromodomain(BRD4(1/2)).

IC50&Target

IC50:77/33nM(BRD4(1/2))[1]

InVitro

(+)-JQ1representsapotent,highlyspecificandKaccompetitiveinhibitorfortheBETfamilyofbromodomains.(+)-JQ1(100nM,48h)promptssquamousdifferentiationexhibitedbycellspindling,flatteningandincreasedexpressionofkeratin.(+)-JQ1(250nM)inducesrapidexpressionofkeratinintreatedNMC797cellscomparedto(-)-JQ1(250nM)andvehiclecontrols,asdeterminedbyquantitativeimmunohistochemistry.(+)-JQ1(250nM)elicitsatime-dependentinductionofstrong(3+)keratinstainingoftreatedNMC797cells,comparedto(-)-JQ1(250nM)[1].(+)-JQ1isapotentthienodiazepineinhibitor(Kd=90nM)oftheBETfamilycoactivatorproteinBRD4,whichisimplicatedinthepathogenesisofcancerviatranscriptionalcontroloftheMYConcogene.Dose-rangingstudiesof(+)-JQ1demonstratespotentinhibitionofH4Kac4bindingwithaIC50valueof10nMformurineBRDT(1)and11nMforhumanBRDT(1)[2].

InVivo

Pharmacokineticstudiesof(+)-JQ1areperformedinCD1micefollowingintravenousandoraladmiNISTration.Meanplasmaconcentration-timeprofilesof(+)-JQ1afterintravenousdosing(5mg/kg).Thepharmacokineticparametersforintravenous(+)-JQ1demonstrateexcellentdrugexposure(AUC=2090hr*ng/mL)andanapproximatelyonehourhalf-life(T1/2).Meanplasmaconcentration-timeprofilesof(+)-JQ1afteroraldosing(10mg/kg).Thepharmacokineticparametersfororal(+)-JQ1demonstrateexcellentoralbioavailABIlity(F=49%),peakplasmaconcentration(Cmax=1180ng/mL)anddrugexposure(AUC=2090hr*ng/mL)[1].

References

  • [1].FilippakopoulosP,etal.SelectiveinhibitionofBETbromodomains.Nature.2010Dec23;468(7327):1067-73.

    [2].MatzukMM,etal.Small-moleculeinhibitionofBRDTformalecontraception.Cell.2012Aug17;150(4):673-84.

    [3].PeirsS,etal.TargetingBETproteinsimprovesthetherapeuticefficacyofBCL-2inhibitioninT-cellacutelymphoblasticleukemia.Leukemia.2017Feb3.

    [4].TögelL,etal.DualTargetingofBromodomainandExtraterminalDomainProteins,andWNTorMAPKSignaling,Inhibitsc-MYCExpressionandProliferationofColorectalCancerCells.MolCancerTher.2016Jun;15(6):1217-26.

    [5].SahniJM,etal.BromodomainandExtraterminalProteinInhibitionBlocksGrowthofTriple-negativeBreastCancersthroughtheSuppressionofAuroraKinases.JBiolChem.2016Nov4;291(45):23756-23768.

    [6].NakamuraY,etal.Targetingofsuper-enhancersandmutantBRAFcansuppressgrowthofBRAF-mutantcoloncancercellsviarepressionofMAPKsignalingpathway.CancerLett.2017Aug28;402:100-109.

    [7].BhattacharyyaS,etal.Alteredhydroxymethylationisseenatregulatoryregionsinpancreaticcancerandregulatesoncogenicpathways.GenomeRes.2017Nov;27(11):1830-1842.

PreparingStockSolutions
ConcentrationVolumeMass1mg5mg10mg
1mM2.1882mL10.9412mL21.8823mL
5mM0.4376mL2.1882mL4.3765mL
10mM0.2188mL1.0941mL2.1882mL
Pleaserefertothesolubilityinformationtoselecttheappropriatesolvent.
CellAssay
[1]

(+)-JQ1isdissolvedinDMSOandstored,andthendilutedwithappropriatemedia(DMSO0.025%)beforeuse[1].

NUTmidlinecarcinomapatientcelllines(797and11060)areplatedinT-25flasksandgrowninDMEM(797)orRPMI(11060)containing10%fetalbovineserumand1%Penicillin/Streptomycin.Cellsaretreatedwitheither250nM(+)-JQ1,250nM(-)-JQ1ortheequivalentvolumeofDMSO(0.025%).Atthedesiredtimepoint,2×106cellsarespunat500×gfor5minutesat4°CandwashedwithPBS.PelletsareresUSPendedin1mLofcoldPBSandaddeddropwisewhilegentlyvortexingto9mL70%ethanolina15mLpolypropylenecentrifugetube.Fixedcellsarethenfrozenat-20°Covernight.Thenextday,cellsarecentrifugedat500×gfor10minutesat4°Candwashedwith3mLofcoldPBS.Cellsareresuspendedin500μLofpropidiumiodidestainingsolution(0.2mg/mLRNAseA,0.02mg/mLpropidiumiodide,0.1%Triton-XinPBS)andincubatedfor20minutesat37°C.SamplesarethentransferredtoiceandanalyzedonaBDFACSCantoII.HistogramsaregeneratedandcellcycleanalysisisperformedusingFlowJoflowcytometryanalysissoftware[1].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.

AnimalAdministration
[1][2]

(+)-JQ1isformulatedforintravenousinjectionin10%DMSOand10%HP-β-CD(Mice)[1].
(+)-JQ1isformulatedinsaline,10%2-Hydroxypropyl-β-cyclodextrinand10%DMSO(Rat)[2].

Mice[1]
MaleCD1mice(24-29g)aretreatedwithasingledoseof(+)-JQ1at5mg/kgforintravenoustailveininjectionstudiesand10mg/kgfororalgavagestudies.Approximately150μLofbloodaretakenfromanimalsbyretro-orbitalpunctureunderanesthesiawithIsofluraneintoEDTAtubesatpre-specifiedtimeintervals:0.033,0.083,0.25,0.5,1,2,4,5,8and24hours.Threeanimalsareanalyzedpertimepoint.Bloodsamplesareputoniceandcentrifugedtoobtainplasmasamples(2000×g,5minunder4°C)within15minutespost-sampling.Plasmasamplesarestoredatapproximately-70°Cuntilanalysisisperformed.Miceareprovidedfreeaccesstofoodandwaterthroughoutthestudy.
Rat[2]
AdultmaleSprague-Dawleyratsaretreatedwithvehicleor(+)-JQ1(10mg/kg).TreatmentisadministeredIPat1/100bodymass.Ratsarecheckedtwice-dailyformortalityandweighedondays1,3,7,14,and21.Thetreatmentregimenutilized4daysof50mg/kgJQ1administereddailywhichisdecreasedto10mg/kgtwicedailyfortheremainderofthestudyduetotheappearanceofadverseeffectsinasubsetofanimals.Forallanimalscompleting3weeksoftreatment,testismass,spermmotility,andspermcountsaredeterminedasdescribedformousestudies.Inbrief,testesarefixedinBouin’sandpreparedforhistology.TheotherhalfismincedinwarmM16bufferandusedforspermcountsandmotilitystudies.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.

References

  • [1].FilippakopoulosP,etal.SelectiveinhibitionofBETbromodomains.Nature.2010Dec23;468(7327):1067-73.

    [2].MatzukMM,etal.Small-moleculeinhibitionofBRDTformalecontraception.Cell.2012Aug17;150(4):673-84.

    [3].PeirsS,etal.TargetingBETproteinsimprovesthetherapeuticefficacyofBCL-2inhibitioninT-cellacutelymphoblasticleukemia.Leukemia.2017Feb3.

    [4].TögelL,etal.DualTargetingofBromodomainandExtraterminalDomainProteins,andWNTorMAPKSignaling,Inhibitsc-MYCExpressionandProliferationofColorectalCancerCells.MolCancerTher.2016Jun;15(6):1217-26.

    [5].SahniJM,etal.BromodomainandExtraterminalProteinInhibitionBlocksGrowthofTriple-negativeBreastCancersthroughtheSuppressionofAuroraKinases.JBiolChem.2016Nov4;291(45):23756-23768.

    [6].NakamuraY,etal.Targetingofsuper-enhancersandmutantBRAFcansuppressgrowthofBRAF-mutantcoloncancercellsviarepressionofMAPKsignalingpathway.CancerLett.2017Aug28;402:100-109.

    [7].BhattacharyyaS,etal.Alteredhydroxymethylationisseenatregulatoryregionsinpancreaticcancerandregulatesoncogenicpathways.GenomeRes.2017Nov;27(11):1830-1842.

MolecularWeight

456.99

Formula

C₂₃H₂₅ClN₄O₂S

CASNo.

1268524-70-4

Storage
Powder-20°C3years
 4°C2years
Insolvent-80°C6months
 -20°C1month
Shipping

RoomtemperatureincontinentalUS;mayvaryelsewhere

Solvent&Solubility

DMSO:≥45mg/mL

(+)-JQ-1(JQ1)isformulatedin10%DMSOand90%ofa10%2-hydroxypropyl-β-cyclodextrinsolution[3].
(+)-JQ-1(JQ1)ispreparedinvehicle(20%hydroxypropyl-β-cyclodextrin,5%DMSO,0.2%Tween-80insaline)[4].
(+)-JQ-1(JQ1)ispreparedinvehicle(1:1propyleneglycol:water)[5].
(+)-JQ-1(JQ1)ispreparedinvehicle(5%DMSOin10%2-hydroxypropyl-ß-cyclodextrinsolution)[6].
(+)-JQ-1ispreparedinvehicle(10%hydroxypropylβ-cyclodextrininwater)[7].

*"<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation="">

References

  • [1].FilippakopoulosP,etal.SelectiveinhibitionofBETbromodomains.Nature.2010Dec23;468(7327):1067-73.

    [2].MatzukMM,etal.Small-moleculeinhibitionofBRDTformalecontraception.Cell.2012Aug17;150(4):673-84.

    [3].PeirsS,etal.TargetingBETproteinsimprovesthetherapeuticefficacyofBCL-2inhibitioninT-cellacutelymphoblasticleukemia.Leukemia.2017Feb3.

    [4].TögelL,etal.DualTargetingofBromodomainandExtraterminalDomainProteins,andWNTorMAPKSignaling,Inhibitsc-MYCExpressionandProliferationofColorectalCancerCells.MolCancerTher.2016Jun;15(6):1217-26.

    [5].SahniJM,etal.BromodomainandExtraterminalProteinInhibitionBlocksGrowthofTriple-negativeBreastCancersthroughtheSuppressionofAuroraKinases.JBiolChem.2016Nov4;291(45):23756-23768.

    [6].NakamuraY,etal.Targetingofsuper-enhancersandmutantBRAFcansuppressgrowthofBRAF-mutantcoloncancercellsviarepressionofMAPKsignalingpathway.CancerLett.2017Aug28;402:100-109.

    [7].BhattacharyyaS,etal.Alteredhydroxymethylationisseenatregulatoryregionsinpancreaticcancerandregulatesoncogenicpathways.GenomeRes.2017Nov;27(11):1830-1842.

Purity:99.90%